SEER age-adjusted mortality rates. Rates are displayed for acute and chronic leukemia. The rates for CML are shown (purple triangles). The mortality rates in CML show a steady decline after the introduction of imatinib in the 1990s. By contrast, note the (humbling) lack of improvement in the other subtypes of leukemia.